Ligand Binding Assay Critical Reagents and Their Stability: Recommendations and Best Practices from the Global Bioanalysis Consortium Harmonization Team
暂无分享,去创建一个
M. Ma | P. Sriraman | L. King | Esme Farley | M. Khan | Mami Imazato | Jeannine Keefe | K. Pihl
[1] T. Laird. Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals , 2013 .
[2] Philip Timmerman,et al. The European Bioanalysis Forum community's evaluation, interpretation and implementation of the European Medicines Agency guideline on Bioanalytical Method Validation. , 2013, Bioanalysis.
[3] Tong-Yuan Yang,et al. Characterization of critical reagents in ligand-binding assays: enabling robust bioanalytical methods and lifecycle management. , 2013, Bioanalysis.
[4] T. Randolph,et al. Physical Instability of Peptides and Proteins , 2012 .
[5] Edward Tabler,et al. Validation and life-cycle management of a quantitative ligand-binding assay for the measurement of Nulojix(®), a CTLA-4-Fc fusion protein, in renal and liver transplant patients. , 2012, Bioanalysis.
[6] Denise M O'Hara,et al. Ligand Binding Assays in the 21st Century Laboratory: Recommendations for Characterization and Supply of Critical Reagents , 2012, The AAPS Journal.
[7] T. Munro,et al. Stabilization of a monoclonal antibody during purification and formulation by addition of basic amino acid excipients , 2011 .
[8] Apollon Papadimitriou,et al. Quality requirements for critical assay reagents used in bioanalysis of therapeutic proteins: what bioanalysts should know about their reagents. , 2011, Bioanalysis.
[9] B. Yeung,et al. Physical Stability of Protein Pharmaceuticals , 2010 .
[10] Feroz Jameel,et al. Formulation and process development strategies for manufacturing biopharmaceuticals , 2010 .
[11] K. Chattopadhyay,et al. Role of Protein Stabilizers on the Conformation of the Unfolded State of Cytochrome c and Its Early Folding Kinetics , 2010, The Journal of Biological Chemistry.
[12] Masood N. Khan,et al. Development of Ligand‐Binding Assays for Drug Development Support , 2009 .
[13] P. Krause. Goals of stability evaluation throughout the vaccine life cycle. , 2009, Biologicals : journal of the International Association of Biological Standardization.
[14] Anika Ashok,et al. ICH Harmonised Tripartite Guideline , 2009 .
[15] J. Darden,et al. Guidelines on good clinical laboratory practice: bridging operations between research and clinical research laboratories. , 2008, Journal of pharmaceutical and biomedical analysis.
[16] Alex Ni,et al. Antimicrobial preservative use in parenteral products: past and present. , 2007, Journal of pharmaceutical sciences.
[17] Denise M O'Hara,et al. Critical ligand binding reagent preparation/selection: When specificity depends on reagents , 2007, The AAPS Journal.
[18] Eric Woolf,et al. Best practices during bioanalytical method validation for the characterization of assay reagents and the evaluation of analyte stability in assay standards, quality controls, and study samples , 2007, The AAPS Journal.
[19] Vinod P. Shah,et al. Workshop/conference report—Quantitative bioanalytical methods validation and implementation: Best practices for chromatographic and ligand binding assays , 2007, The AAPS Journal.
[20] David M Bunk,et al. Characterization of a new certified reference material for human cardiac troponin I. , 2006, Clinical chemistry.
[21] Stanley B. Davis,et al. Quality Management , 2005 .
[22] George Scott,et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. , 2004, Journal of immunological methods.
[23] Binodh DeSilva,et al. Recommendations for the Bioanalytical Method Validation of Ligand-Binding Assays to Support Pharmacokinetic Assessments of Macromolecules , 2003, Pharmaceutical Research.
[24] G. Anderson,et al. Determination of product shelf life and activation energy for five drugs of abuse. , 1991, Clinical chemistry.
[25] T. Kirkwood,et al. Predicting the stability of biological standards and products. , 1977, Biometrics.
[26] W Greg Miller,et al. Commutability limitations influence quality control results with different reagent lots. , 2011, Clinical chemistry.
[27] John W. A. Findlay,et al. Ligand-binding assays : development, validation, and implementation in the drug development arena , 2010 .
[28] S. Frokjaer,et al. Pharmaceutical Formulation Development Of Peptides And Proteins , 2009 .
[29] Wei Wang,et al. Antibody structure, instability, and formulation. , 2007, Journal of pharmaceutical sciences.
[30] H. Selbmann. [What is "quality management"?]. , 1995, Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen.
[31] C. Burtis. Tietz textbook of Clinical Chemistry , 1994 .